Louise Stanton

3.0k total citations
36 papers, 856 citations indexed

About

Louise Stanton is a scholar working on Oncology, Pathology and Forensic Medicine and Epidemiology. According to data from OpenAlex, Louise Stanton has authored 36 papers receiving a total of 856 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 14 papers in Pathology and Forensic Medicine and 6 papers in Epidemiology. Recurrent topics in Louise Stanton's work include Lymphoma Diagnosis and Treatment (10 papers), CAR-T cell therapy research (6 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Louise Stanton is often cited by papers focused on Lymphoma Diagnosis and Treatment (10 papers), CAR-T cell therapy research (6 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Louise Stanton collaborates with scholars based in United Kingdom, Switzerland and Australia. Louise Stanton's co-authors include Tom Maishman, Ellen Copson, Lorraine Durcan, Diana Eccles, Gregory M. Peterson, Bryony Eccles, J. Louise Jones, Ramsey Cutress, Peter Simmonds and Douglas G. Altman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Louise Stanton

34 papers receiving 834 citations

Peers

Louise Stanton

ONCOL

EPIDE

PRM

PFM

Aart van Bochove Netherlands

Taha Koray Şahin Türkiye

Alessio Cortellini Italy

Patrick R. Varley United States

Peh Joo Ho Singapore

Lucia Fratino Italy

Geert‐Jan Creemers Netherlands

Encarnación González‐Flores Spain

Érick Moyneur United States

Andrea Antonuzzo Italy

Aart van Bochove Netherlands

Louise Stanton

1.3k ×2.8

ONCOL

115 ×0.6

90 ×0.5

EPIDE

464 ×3.4

PRM

209 ×1.6

PFM

Citations per year, relative to Louise Stanton Louise Stanton (= 1×) peers Aart van Bochove

Countries citing papers authored by Louise Stanton

Since Specialization

Citations

This map shows the geographic impact of Louise Stanton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Louise Stanton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Louise Stanton more than expected).

Fields of papers citing papers by Louise Stanton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Louise Stanton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Louise Stanton. The network helps show where Louise Stanton may publish in the future.

Co-authorship network of co-authors of Louise Stanton

This figure shows the co-authorship network connecting the top 25 collaborators of Louise Stanton. A scholar is included among the top collaborators of Louise Stanton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Louise Stanton. Louise Stanton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stanton, Louise, Sharon Barrans, Jane Rafferty, et al.. (2023). REMODL‐A: A RANDOMISED PHASE II EVALUATION OF MOLECULAR GUIDED THERAPY FOR DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) WITH ACALABRUTINIB — ONGOING TRIAL. Hematological Oncology. 41(S2). 166–167. 2 indexed citations

Davies, Andrew, Josh Caddy, Robert Waugh, et al.. (2022). Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study. Blood. 140(Supplement 1). 9478–9479. 2 indexed citations

Moore, Michael, Fran Webley, Mike Radford, et al.. (2019). Uva-ursi extract and ibuprofen as alternative treatments for uncomplicated urinary tract infection in women (ATAFUTI): a factorial randomized trial. Clinical Microbiology and Infection. 25(8). 973–980. 38 indexed citations

Davies, Andrew, Thomas Cummin, Louise Stanton, et al.. (2019). ARGO: A RANDOMISED PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH‐DOSE THERAPY. Hematological Oncology. 37(S2). 555–556.

Lim, Sean H., Kim Linton, Graham P. Collins, et al.. (2018). RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial. Trials. 19(1). 619–619. 8 indexed citations

Bridgewater, John, S. Pugh, Amy Whitehead, et al.. (2017). Perioperative chemotherapy with or without cetuximab in patients (pts) with resectable colorectal liver metastasis (CRLM): Mature analysis of overall survival (OS) in the New EPOC randomised controlled trial. Annals of Oncology. 28. v162–v162. 3 indexed citations

Simpson, Catherine, Mike Radford, Louise Stanton, et al.. (2017). Uva-ursi extract and ibuprofen as alternative treatments of adult female urinary tract infection (ATAFUTI): study protocol for a randomised controlled trial. Trials. 18(1). 421–421. 13 indexed citations

Eccles, Diana, Tom Maishman, William Tapper, et al.. (2017). Abstract S2-03: Does BRCA status affect outcome in young breast cancer patients? Results from the prospective study of outcomes in sporadic and hereditary breast cancer (POSH). Cancer Research. 77(4_Supplement). S2–3. 3 indexed citations

Arriola, Edurne, Matthew Wheater, Ian Galea, et al.. (2016). Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. Journal of Thoracic Oncology. 11(9). 1511–1521. 97 indexed citations

10.

Davies, Andrew, Ming Wang, Ming‐Qing Du, et al.. (2015). Real-Time Molecular Classification of Diffuse Large B-Cell Lymphoma (DLBCL) By Gene Expression Profiling (GEP): Successful Delivery of a Routine Service for Randomization of Patients Onto the Multicenter Remodl-B Trial (ISRCTN 51837425). Blood. 126(23). 331–331. 1 indexed citations

11.

Maishman, Tom, Ellen Copson, Louise Stanton, et al.. (2015). An evaluation of the prognostic model PREDICT using the POSH cohort of women aged ⩽40 years at breast cancer diagnosis. British Journal of Cancer. 112(6). 983–991. 30 indexed citations

12.

Copson, Ellen, Ramsey Cutress, Tom Maishman, et al.. (2014). Obesity and the outcome of young breast cancer patients in the UK: the POSH study. Annals of Oncology. 26(1). 101–112. 65 indexed citations

13.

Turner, Sheila, et al.. (2014). Features of successful bids for funding of applied health research: a cohort study. Health Research Policy and Systems. 12(1). 54–54. 1 indexed citations

14.

McCann, Donna, Margaret Thompson, David Daley, et al.. (2014). Study protocol for a randomized controlled trial comparing the efficacy of a specialist and a generic parenting programme for the treatment of preschool ADHD. Trials. 15(1). 142–142. 10 indexed citations

15.

Copson, Ellen, Tom Maishman, Susan M. Gerty, et al.. (2013). Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study. British Journal of Cancer. 110(1). 230–241. 56 indexed citations

16.

Forrest, Ewan, J. M. MELLOR, Louise Stanton, et al.. (2013). Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials. 14(1). 262–262. 49 indexed citations

17.

Copson, Ellen, Bryony Eccles, Tom Maishman, et al.. (2013). Prospective Observational Study of Breast Cancer Treatment Outcomes for UK Women Aged 18–40 Years at Diagnosis: The POSH Study. JNCI Journal of the National Cancer Institute. 105(13). 978–988. 141 indexed citations

18.

Peterson, Gregory M., et al.. (1997). Improving the prescribing of antibiotics for urinary tract infection. Journal of Clinical Pharmacy and Therapeutics. 22(2). 147–153. 25 indexed citations

19.

Peterson, Gregory M., et al.. (1996). Improving drug use in rheumatic disorders. Journal of Clinical Pharmacy and Therapeutics. 21(4). 215–220. 14 indexed citations

20.

Stanton, Louise, Gregory M. Peterson, Roger Rumble, Gabrielle Cooper, & Alan E. Polack. (1994). Drug-related admissions to an Australian hospital. Journal of Clinical Pharmacy and Therapeutics. 19(6). 341–347. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact